Evaluation of α-Synuclein and Apolipoprotein E as Potential Biomarkers in Cerebrospinal Fluid to Monitor Pharmacotherapeutic Efficacy in Dopamine Dictated Disease States of Parkinson’s Disease and Schizophrenia [Corrigendum]

Abstract

Gupta AK, Pokhriyal R, Das U, et al. Neuropsychiatr Dis Treat. 2019;15:2073–2085. The authors wish to advise of typographical errors in Figures 1 and 2 and Table 3, the correct unit of apolipoprotein E concentration is μg/ml, and not pg/ml. Page 2077, Figure 1A, y axis, the text “CSF apolipoprotein E (pg/ml)” should read “CSF apolipoprotein E (μg/ml)”. Page 2077, Figure 2, x axis, the text “CSF apolipoprotein E (pg/ml)” should read “CSF apolipoprotein E (µg/ml)”. Page 2079, Table 3, Cut-off values to differentiate neurological controls from the disease column, Apolipoprotein E and Apolipoprotein E or α-synuclein rows, the text “>3.4 pg (Parkinson’s disease)” should read “>3.4 µg (Parkinson’s disease)” and “ The authors apologize for these errors and any inconvenience. Read the original article

Keywords

• cerebro-spinal fluid
• parkinson’s disease
• schizophrenia
• dopamine
• apolipoprotein e
• α-synuclein
• biomarkers
• treatment monitoring